新型正电子发射断层显像（PET）示踪剂用于前列腺癌成像
Prostate Cancer Imaging with Novel PET Tracers.
作者信息
Lindenberg Liza, Choyke Peter, Dahut William
机构信息
Center for Cancer Research, National Cancer Institute, BG 10-CRC RM 3-2571 MSC 1206, 10 Center Dr, Bethesda, MD, 20892-1206, USA.
Molecular Imaging Program, National Cancer Institute, BG 10 RM B3B69F MS 1002, 10 Center Dr, Bethesda, MD, 20814, USA.
出版信息
Curr Urol Rep. 2016 Mar;17(3):18. doi: 10.1007/s11934-016-0575-5.
Abstract
Molecular imaging of prostate cancer is in a dynamic phase of development. Currently approved techniques are limited and researchers have been working on novel agents to improve accuracy in targeting and detecting prostate tumors. In addition, the complexity of various prostate cancer states also contributes to the challenges in evaluating suitable radiotracer candidates. We have highlighted nuclear medicine tracers that focus on mechanisms involved in bone metastasis, prostate cancer cell membrane synthesis, amino acid analogs, androgen analogs, and the prostate specific membrane antigen. Encouraging results with many of these innovative radiotracer compounds will not only advance diagnostic capabilities for prostate cancer but open opportunities for theranostic applications to treat this worldwide malignancy.
摘要
前列腺癌的分子成像正处于动态发展阶段。目前获批的技术有限，研究人员一直在致力于研发新型药物，以提高前列腺肿瘤靶向和检测的准确性。此外，各种前列腺癌状态的复杂性也给评估合适的放射性示踪剂候选物带来了挑战。我们重点介绍了聚焦于骨转移、前列腺癌细胞膜合成、氨基酸类似物、雄激素类似物以及前列腺特异性膜抗原相关机制的核医学示踪剂。许多这些创新性放射性示踪剂化合物取得的令人鼓舞的结果，不仅将推动前列腺癌的诊断能力提升，还将为治疗这种全球范围内的恶性肿瘤的诊疗应用带来机遇。
相似文献
1
Prostate Cancer Imaging with Novel PET Tracers.新型正电子发射断层显像（PET）示踪剂用于前列腺癌成像
Curr Urol Rep. 2016 Mar;17(3):18. doi: 10.1007/s11934-016-0575-5.
2
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
3
A Prospective Comparison of F-Sodium Fluoride PET/CT and PSMA-Targeted F-DCFBC PET/CT in Metastatic Prostate Cancer.F-氟钠 PET/CT 与 PSMA 靶向 F-DCFBC PET/CT 对转移性前列腺癌的前瞻性比较
J Nucl Med. 2018 Nov;59(11):1665-1671. doi: 10.2967/jnumed.117.207373. Epub 2018 Mar 30.
4
New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.（18）F/（11）C-胆碱的新临床适应证、正电子发射断层扫描的新型示踪剂和用于前列腺癌分期的有前途的混合设备：文献系统评价。
Eur Urol. 2016 Jul;70(1):161-175. doi: 10.1016/j.eururo.2016.01.029. Epub 2016 Feb 2.
5
Prostate cancer PET tracers: essentials for the urologist.前列腺癌PET示踪剂：泌尿外科医生须知要点
Can J Urol. 2018 Aug;25(4):9371-9383.
6
New aspects of molecular imaging in prostate cancer.前列腺癌分子影像学的新方面。
Methods. 2017 Nov 1;130:36-41. doi: 10.1016/j.ymeth.2017.07.009. Epub 2017 Jul 13.
7
Small Molecule, Multimodal, [F]-PET and Fluorescence Imaging Agent Targeting Prostate-Specific Membrane Antigen: First-in-Human Study.小分子、多模式、[F]-PET 和荧光成像剂靶向前列腺特异性膜抗原：首例人体研究。
Clin Genitourin Cancer. 2021 Oct;19(5):405-416. doi: 10.1016/j.clgc.2021.03.011. Epub 2021 Mar 19.
8
Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.比较（68）Ga 标记的 PSMA 配体与基于（18）F-胆碱的 PET/CT 在诊断复发性前列腺癌中的作用。
Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):11-20. doi: 10.1007/s00259-013-2525-5. Epub 2013 Sep 27.
9
Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.Ga 标记前列腺特异性膜抗原配体正电子发射断层扫描/计算机断层扫描在前列腺癌中的应用：系统评价和荟萃分析。
Eur Urol Focus. 2018 Sep;4(5):686-693. doi: 10.1016/j.euf.2016.11.002. Epub 2016 Nov 15.
10
Whole-Body Integrated [Ga]PSMA-11-PET/MR Imaging in Patients with Recurrent Prostate Cancer: Comparison with Whole-Body PET/CT as the Standard of Reference.全身整合 [Ga]PSMA-11-PET/MR 成像在复发性前列腺癌患者中的应用：与全身 PET/CT 作为参考标准的比较。
Mol Imaging Biol. 2020 Jun;22(3):788-796. doi: 10.1007/s11307-019-01424-4.
引用本文的文献
1
Normal Variants, Pitfalls, and Artifacts in Ga-68 Prostate Specific Membrane Antigen (PSMA) PET/CT Imaging.镓-68前列腺特异性膜抗原（PSMA）PET/CT成像中的正常变异、陷阱与伪影
Front Nucl Med. 2022 Feb 21;2:825512. doi: 10.3389/fnume.2022.825512. eCollection 2022.
2
Imaging assessment of prostate cancer recurrence: advances in detection of local and systemic relapse.前列腺癌复发的影像学评估：局部和全身复发检测的进展
Abdom Radiol (NY). 2025 Feb;50(2):807-826. doi: 10.1007/s00261-024-04412-7. Epub 2024 Sep 10.
3
Comparison of PSMA-based F-DCFPyL PET/CT and Tc-99m MDP bone scan in detection of bone metastasis in prostate cancer.基于前列腺特异性膜抗原（PSMA）的F-DCFPyL正电子发射断层扫描/计算机断层扫描（PET/CT）与锝-99m亚甲基二膦酸盐（Tc-99m MDP）骨扫描在前列腺癌骨转移检测中的比较
Am J Nucl Med Mol Imaging. 2023 Feb 15;13(1):1-10. eCollection 2023.
4
Comparing the diagnostic performance of radiotracers in prostate cancer biochemical recurrence: a systematic review and meta-analysis.比较放射性示踪剂在前列腺癌生化复发中的诊断性能：系统评价和荟萃分析。
Eur Radiol. 2022 Nov;32(11):7374-7385. doi: 10.1007/s00330-022-08802-7. Epub 2022 Apr 29.
5
Imaging of Neuroendocrine Prostatic Carcinoma.神经内分泌前列腺癌的影像学检查
Cancers (Basel). 2021 Nov 17;13(22):5765. doi: 10.3390/cancers13225765.
6
FDG-PET Versus PSMA-PET: A Patient With Prostate Cancer.FDG-PET 与 PSMA-PET：一位前列腺癌患者。
J Investig Med High Impact Case Rep. 2020 Jan-Dec;8:2324709620941313. doi: 10.1177/2324709620941313.
7
Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials.在接受恩杂鲁胺治疗的转移性去势抵抗性前列腺癌男性中，新的未确认骨病变与结局之间的关联：PREVAIL 和 AFFIRM 随机临床试验的二次分析。
JAMA Oncol. 2020 Feb 1;6(2):217-225. doi: 10.1001/jamaoncol.2019.4636.
8
Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer.利用CD133对致命性前列腺癌进行靶向成像。
Clin Cancer Res. 2020 Mar 1;26(5):1054-1064. doi: 10.1158/1078-0432.CCR-19-1659. Epub 2019 Nov 15.
9
Ultrasmall Renally Clearable Silica Nanoparticles Target Prostate Cancer.超小肾清除二氧化硅纳米颗粒靶向前列腺癌。
ACS Appl Mater Interfaces. 2019 Nov 27;11(47):43879-43887. doi: 10.1021/acsami.9b15195. Epub 2019 Nov 13.
10
PSMA-targeting agents for radio- and fluorescence-guided prostate cancer surgery.用于放射性和荧光引导前列腺癌手术的 PSMA 靶向剂。
Theranostics. 2019 Sep 20;9(23):6824-6839. doi: 10.7150/thno.36739. eCollection 2019.
本文引用的文献
1
Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography.通过68Ga-PSMA正电子发射断层扫描/计算机断层扫描检测到的淋巴结寡转移前列腺癌的盆腔淋巴结清扫术
Prostate. 2015 Dec;75(16):1934-40. doi: 10.1002/pros.23091. Epub 2015 Sep 10.
2
The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.治疗诊断用前列腺特异性膜抗原（PSMA）配体PSMA-617在PET/CT诊断前列腺癌中的应用：人体生物分布、辐射剂量测定及肿瘤病变的首次评估
J Nucl Med. 2015 Nov;56(11):1697-705. doi: 10.2967/jnumed.115.161299. Epub 2015 Aug 20.
3
Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [(11) C]acetate PET as a prognostic marker.脂肪酸合酶在前列腺癌复发中的评估：[(11)C]乙酸PET的SUV作为一种预后标志物
Prostate. 2015 Nov;75(15):1760-7. doi: 10.1002/pros.23061. Epub 2015 Aug 18.
4
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.一项关于89Zr-J591免疫正电子发射断层显像（ImmunoPET）作为转移性前列腺癌分子成像剂的分析验证的I/II期研究。
Clin Cancer Res. 2015 Dec 1;21(23):5277-85. doi: 10.1158/1078-0432.CCR-15-0552. Epub 2015 Jul 14.
5
PSMA PET/CT with Glu-urea-Lys-(Ahx)-[⁶⁸Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer.用于复发性前列腺癌的PSMA PET/CT与Glu-尿素-Lys-(Ahx)-[⁶⁸Ga(HBED-CC)]对比3D CT容积性淋巴结评估
Eur J Nucl Med Mol Imaging. 2015 Nov;42(12):1794-800. doi: 10.1007/s00259-015-3106-6. Epub 2015 Jul 11.
6
Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.(68)Ga-PSMA PET/CT 成像在根治性前列腺切除术前行高危前列腺癌患者中的初步经验。
Eur Urol. 2016 Mar;69(3):393-6. doi: 10.1016/j.eururo.2015.06.010. Epub 2015 Jun 25.
7
Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.18F-氟甲基胆碱与 68Ga-PSMA PET/CT 在经治愈性治疗后 PSA 升高且正在考虑靶向治疗的前列腺癌患者中的前瞻性比较。
J Nucl Med. 2015 Aug;56(8):1185-90. doi: 10.2967/jnumed.115.160382. Epub 2015 Jun 25.
8
Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study.用（177）Lu-DKFZ-617 PSMA进行放射性配体治疗去势抵抗性转移性前列腺癌的早期副作用和初步结果：一项双中心研究
EJNMMI Res. 2015 Dec;5(1):114. doi: 10.1186/s13550-015-0114-2. Epub 2015 Jun 20.
9
Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival.223Ra 治疗患者的预后因素：基线 18F-氟代脱氧葡萄糖 PET/CT 中骨骼肿瘤负荷对总生存的预测作用。
J Nucl Med. 2015 Aug;56(8):1177-84. doi: 10.2967/jnumed.115.158626. Epub 2015 Jun 11.
10
¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.基于¹⁸F-DCFBC的PET/CT用于原发性前列腺癌基于前列腺特异性膜抗原的检测与特征分析
J Nucl Med. 2015 Jul;56(7):1003-1010. doi: 10.2967/jnumed.115.154336. Epub 2015 Jun 11.
Zotero 插件